Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane

Cancer Chemotherapy and Pharmacology
Hironaga SatakeAkihito Tsuji

Abstract

Optimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the first molecularly targeted agent proven to be effective in second-line therapy for AGC in combination with chemotherapy. We sought to determine the maximum tolerated dose (MTD) and recommended dose (RD) of ramucirumab plus irinotecan for AGC previously treated with fluoropyrimidine with/without platinum and taxane. Patients received systemic chemotherapy with ramucirumab (8 mg/kg) and irinotecan on day 1, repeated every 2 weeks. A decrease in irinotecan dose was planned from start level 1 (irinotecan 150 mg/m2). This trial was registered with the University Hospital Medical Network (UMIN no. 000018606). Six patients were enrolled from August 2015 to September 2017. No dose-limiting toxicity (DLT) was observed, and the maximum tolerated dose (MTD) was not reached at level 1. Irinotecan 150 mg/m2 in combination with ramucirumab 8 mg/kg was administered with acceptable toxicity, and all patients were treated at these doses. No treatment-related deaths were observed. Adverse events...Continue Reading

References

Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJ Randolph Hecht
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L AssersohnA R Norman
Mar 17, 2004·Japanese Journal of Clinical Oncology·Jong Ho ChunJae-Moon Bae
Aug 31, 2007·Journal of the National Cancer Institute·Janelle M HoskinsHoward L McLeod
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salah-Eddin Al-BatranUNKNOWN Arbeitsgemeinschaft Internistische Onkologie
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y-K KangP I McCloud
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Oct 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Nov 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YoshinoJ-Y Douillard
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo

❮ Previous
Next ❯

Citations

Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh

❮ Previous
Next ❯

Software Mentioned

RINDBeRG
RECIST
SPSS

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.